The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the be­gin­ning of the year, we got a close-up look at what hap­pens af­ter a boom rip­ples through biotech. The crash of life sci­ences stocks in Q1 was heard around the world.

In the months since, we’ve seen the nat­ur­al Dar­win­ian down cy­cle take ef­fect. Re­verse merg­ers made a come­back, with more burned out shells to go pub­lic at a time IPOs and road shows are out of fa­vor. And no doubt some of the more re­cent ar­rivals on the in­vest­ing side of the busi­ness are find­ing green­er pas­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA